RICHMOND, Va., Dec 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced today that it will present at the IBC 5th Annual Global Follow-On Biologics Conference on December 11, 2007 at 09:15 AM Eastern Time.
The conference, to be held at the Hyatt Regency Hotel in Reston, Virginia, will run from Monday, December 10th through Tuesday, December 11th, and will bring together corporate, regulatory, financial, and legal experts in the field of follow-on biologics. Geoffrey Allan, Ph.D., Insmed President and CEO, will discuss Insmed's comprehensive portfolio of follow-on biologics. His presentation, entitled, "The Development of a Broad Portfolio of Follow-On Biologics: Clinical/Regulatory/Analytical and Commercial Challenges and Strategies," will also highlight Insmed's strategy for providing patients greater choice through access to these innovative follow-on biologics.
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
